甲状腺刺激抗体与Graves眼病临床特点的关系

Association of thyroid-stimulating antibody with the clinical characteristics of Graves' ophthalmopathy

比较分析32例初诊的Graves眼病(GO)患者和27例无眼病Graves病(GD)患者甲状腺刺激抗体(TSAb)与临床特点的关系；并且分析影响糖皮质激素冲击治疗GO预后的因素,发现GO组TSAb水平明显高于GD组,且对预后有显著影响,提示TSAb可能是TSH受体抗体中与眼病损伤更为密切的抗体成分,可作为GO的预测指标。

Clinical features and thyroid-stimulating antibody （TSAb） in 32 newly diagnosed patients with Graves＇ ophthalmopathy （GO） were compared with those in 27 Graves＇ disease （GD） patients without GO （as control group）. All of the patients with GO received intravenous glucocorticoids. The level of serum TSAb in patients with GO was significantly higher than that in patients without GO. TSAb was also associated with the prognosis. It suggests that TSAb seems to be the most active component among the TSH receptor antibodies related to ophthalmopathy and may act as a predictive parameter.